Aleglitazar: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 1: | Line 1: | ||
== Aleglitazar == | |||
[[File:Aleglitazar.svg|thumb|right|Chemical structure of Aleglitazar]] | |||
'''Aleglitazar''' is a [[pharmaceutical drug]] that was developed as a dual [[peroxisome proliferator-activated receptor]] (PPAR) agonist, targeting both the PPAR_ and PPAR_ subtypes. It was investigated for its potential use in the treatment of [[type 2 diabetes mellitus]] and associated [[cardiovascular disease]]. | |||
Aleglitazar | |||
=== | === Mechanism of Action === | ||
Aleglitazar functions by activating the PPAR_ and PPAR_ receptors, which play key roles in the regulation of [[lipid metabolism]] and [[glucose homeostasis]]. Activation of PPAR_ leads to increased [[fatty acid oxidation]] and improved [[lipid profile]], while PPAR_ activation enhances [[insulin sensitivity]] and glucose uptake in [[adipose tissue]]. | |||
PPAR_ | |||
==Clinical | === Development and Clinical Trials === | ||
Aleglitazar was developed by [[Hoffmann-La Roche]] and underwent several phases of clinical trials. The drug showed promise in early studies by improving glycemic control and lipid parameters in patients with type 2 diabetes. However, later-stage trials raised concerns about its safety profile, particularly regarding [[heart failure]] and [[renal impairment]]. | |||
== | === Safety and Efficacy === | ||
The safety concerns observed in clinical trials included an increased risk of [[congestive heart failure]], [[bone fractures]], and [[renal dysfunction]]. These adverse effects led to the discontinuation of its development for the treatment of type 2 diabetes. | |||
=== Conclusion === | |||
Despite its initial promise as a dual PPAR agonist, Aleglitazar's development was halted due to safety concerns. The case of Aleglitazar highlights the challenges in developing drugs that target multiple pathways and the importance of thorough safety evaluations in the drug development process. | |||
== Related Pages == | |||
* [[Type 2 diabetes mellitus]] | * [[Type 2 diabetes mellitus]] | ||
* [[Peroxisome proliferator-activated receptor]] | * [[Peroxisome proliferator-activated receptor]] | ||
* [[Insulin resistance]] | * [[Insulin resistance]] | ||
* [[Cardiovascular disease]] | |||
[[Category:Pharmaceutical drugs]] | |||
[[Category:Diabetes treatments]] | |||
[[Category: | |||
[[Category: | |||
Latest revision as of 03:58, 13 February 2025
Aleglitazar[edit]
Aleglitazar is a pharmaceutical drug that was developed as a dual peroxisome proliferator-activated receptor (PPAR) agonist, targeting both the PPAR_ and PPAR_ subtypes. It was investigated for its potential use in the treatment of type 2 diabetes mellitus and associated cardiovascular disease.
Mechanism of Action[edit]
Aleglitazar functions by activating the PPAR_ and PPAR_ receptors, which play key roles in the regulation of lipid metabolism and glucose homeostasis. Activation of PPAR_ leads to increased fatty acid oxidation and improved lipid profile, while PPAR_ activation enhances insulin sensitivity and glucose uptake in adipose tissue.
Development and Clinical Trials[edit]
Aleglitazar was developed by Hoffmann-La Roche and underwent several phases of clinical trials. The drug showed promise in early studies by improving glycemic control and lipid parameters in patients with type 2 diabetes. However, later-stage trials raised concerns about its safety profile, particularly regarding heart failure and renal impairment.
Safety and Efficacy[edit]
The safety concerns observed in clinical trials included an increased risk of congestive heart failure, bone fractures, and renal dysfunction. These adverse effects led to the discontinuation of its development for the treatment of type 2 diabetes.
Conclusion[edit]
Despite its initial promise as a dual PPAR agonist, Aleglitazar's development was halted due to safety concerns. The case of Aleglitazar highlights the challenges in developing drugs that target multiple pathways and the importance of thorough safety evaluations in the drug development process.
